Inhalant-related disorders involve the intentional inhalation of volatile hydrocarbons, aerosols, gases, and nitrites to produce psychoactive effects, and they are among the most neurotoxic substances of abuse encountered in psychiatry. places , , and unspecified inhalant-related disorder within the broader chapter, while explicitly excluding nitrous oxide and nitrites from the use-disorder category because their pharmacology and clinical course differ. Use is concentrated in early adolescence, often precedes other substance use, and is associated with , irreversible leukoencephalopathy, peripheral neuropathy, and high rates of psychiatric and social comorbidity. No pharmacotherapy is approved for inhalant use disorder, and management rests on identification, supportive care for acute intoxication, treatment of medical and neurological sequelae, and psychosocial intervention. Bottom line: recognize inhalants in any adolescent with unexplained neurological, cardiac, or behavioral findings, and do not delay neurotoxicity workup while pursuing the substance-use history.
Inhalant misuse peaks earlier than any other substance class, with availability and low cost driving disproportionate use in young adolescents and socioeconomically disadvantaged populations. Patterns differ sharply between volatile solvents (used heavily by adolescents) and nitrites (used predominantly by adult men in sexual contexts).
Prevalence and demographics
- Lifetime prevalence of inhalant use among US adolescents is approximately 8-10%, with past-year use among 8th graders historically exceeding that of cocaine and hallucinogens combined.[1-2]
- Inhalants are one of the few substance classes for which 8th-grade past-year use exceeds 12th-grade use, reflecting early initiation and migration to other substances with age.[2]
- Mean age of first use is approximately 13 years; initiation before age 13 confers elevated risk of later substance use disorder.[1,3]
- Sex ratio is roughly equal in early adolescence, with male predominance emerging by late adolescence and adulthood.[1]
- Nitrite ("poppers") use is concentrated among adult men who have sex with men and is associated with HIV risk behaviors.[4]
Risk factors and comorbidity
- Childhood adversity, parental substance use, , and academic failure are robust predictors of inhalant initiation.[1,3]
- Indigenous and remote-community youth in multiple countries (Australia, Canada, US) carry disproportionately high prevalence, with petrol (gasoline) sniffing being historically prominent.[5]
- Inhalant users meet criteria for at least one comorbid psychiatric disorder in the majority of cases, most commonly conduct disorder, ADHD, depressive disorders, and other substance use disorders.[1,3]
- Inhalant use disorder is associated with elevated lifetime suicide attempt rates compared with non-users and with users of other single substance classes.[3]
Inhalants are a pharmacologically heterogeneous group unified by route rather than mechanism, but most produce rapid central nervous system depression through enhancement of GABA-A and glycine receptor activity and inhibition of NMDA glutamate receptors.[6-7]
Pharmacology by class
- Volatile solvents (toluene, xylene, n-hexane, trichloroethylene): lipophilic; rapid pulmonary absorption produces peak CNS levels within seconds; mechanism resembles a short-acting general anesthetic.[6-7]
- Fuel gases and aerosol propellants (butane, propane, difluoroethane, tetrafluoroethane): sensitize the myocardium to catecholamines, the substrate of Sudden sniffing death.[6,8]
- Nitrous oxide: NMDA antagonist; inactivates vitamin B12 by oxidizing cobalt, producing functional B12 deficiency and subacute combined degeneration with chronic use.[9]
- Alkyl nitrites (amyl, butyl, isobutyl nitrite): smooth muscle relaxants via nitric oxide release; produce vasodilation rather than CNS depression, and are pharmacologically distinct from other inhalants.[4,6]
Neurotoxicity
- Toluene produces a characteristic diffuse leukoencephalopathy with cerebellar, brainstem, and corticospinal tract involvement, visible on MRI as T2 hyperintensity and loss of gray-white differentiation.[10-11]
- n-Hexane and nitrous oxide produce length-dependent peripheral neuropathy; n-hexane through its metabolite 2,5-hexanedione and nitrous oxide via B12 inactivation.[9,12]
- Chronic toluene exposure is associated with cognitive impairment, cerebellar ataxia, optic neuropathy, and sensorineural hearing loss.[10-11]
Genetics and environment
- Heritability estimates for inhalant use are lower and less well characterized than for alcohol or cannabis use disorders; environmental factors (availability, peer use, supervision) dominate initiation.[3]
- Polysubstance use is the rule rather than the exception, complicating attribution of psychiatric and cognitive findings to inhalants alone.[1,3]
DSM-5-TR recognizes three inhalant-related diagnoses: Inhalant use disorder, Inhalant intoxication, and unspecified inhalant-related disorder. Inhalant withdrawal is not a recognized DSM-5-TR diagnosis because evidence for a reliable withdrawal is insufficient.[13]
Inhalant use disorder
- Defined as a problematic pattern of hydrocarbon-based inhalant use leading to clinically significant impairment or distress, with at least two of eleven criteria within a 12-month period.[13]
- The eleven criteria follow the standard substance use disorder template: impaired control (criteria 1-4), social impairment (5-7), risky use (8-9), and pharmacological criteria — tolerance (10) and withdrawal (11). DSM-5-TR notes that withdrawal has not been established for inhalants, so criterion 11 is rarely met.[13]
- Severity is graded by criterion count: mild (2-3), moderate (4-5), severe (6 or more).[13]
- Course specifiers: in early remission (3-12 months), in sustained remission (>=12 months), in a controlled environment, on maintenance therapy.[13]
- Critically, the inhalant use disorder diagnosis applies only to hydrocarbon-based inhalants (solvents, fuels, aerosols). Nitrous oxide and nitrite use are coded as "other (or unknown) substance use disorder" if diagnostic criteria are met.[13]
Inhalant intoxication
- Requires recent intentional short-term, high-dose exposure or unintended exposure to a volatile hydrocarbon, clinically significant maladaptive behavioral or psychological changes during or shortly after use, and at least two of: dizziness, nystagmus, incoordination, slurred speech, unsteady gait, lethargy, depressed reflexes, , tremor, generalized muscle weakness, blurred vision or diplopia, stupor or coma, euphoria.[13]
- Symptoms are not attributable to another medical condition or mental disorder, including intoxication with another substance.[13]
GASES
Gait unsteady, Ataxia and incoordination, Slurred speech, Eye signs (nystagmus, blurred vision, diplopia), Stupor or euphoria.
ICD-11 differences
- groups disorders due to use of volatile inhalants under code 6C4B and includes harmful use, dependence, intoxication, and inhalant-induced mental disorders.[14]
- ICD-11 recognizes inhalant withdrawal as a coded entity, in contrast to DSM-5-TR.[14]
DSM-5-TR explicitly excludes anesthetic gases (e.g., halothane) used medically and short-acting vasodilators (nitrites) used medically from the diagnosis; the diagnosis targets recreational, intentional use for psychoactive effect.[13]
Acute intoxication resembles alcohol intoxication with a much shorter time course, while chronic use produces a recognizable constellation of dermatologic, neurological, and behavioral findings. The volatile nature of the substances means duration of intoxication is typically 15-45 minutes; users redose repeatedly during a session to maintain effect.[6-7]
Acute intoxication
- Onset within seconds of inhalation; peak effect within minutes; resolution within 15-45 minutes for most agents.[6-7]
- Initial euphoria, disinhibition, and (visual, auditory, and somatic) progress to ataxia, dysarthria, and stupor with continued exposure.[6-7]
- Cardiac dysrhythmias, including ventricular fibrillation, can occur with fuel gas and aerosol propellant use, particularly when use is followed by sudden exertion or startle.[6,8]
Sudden sniffing death is the most acute lethal complication of inhalant use; it occurs when sensitized myocardium develops a fatal arrhythmia after a catecholamine surge.[6,8]
Chronic-use findings
- "Glue sniffer's rash": perioral and perinasal erythema, eczema, and contact dermatitis from repeated solvent exposure to skin.[6]
- Solvent odor on breath, clothing, or hair; paint or chemical staining on hands or face.[6]
- Cognitive impairment with executive dysfunction, slowed processing speed, and memory deficits, often disproportionate to age and education.[10-11]
- Cerebellar signs (ataxia, intention tremor, dysarthria) and pyramidal signs in advanced toluene leukoencephalopathy.[10-11]
- Peripheral neuropathy with stocking-glove sensory loss and distal weakness in n-hexane and chronic nitrous oxide users.[9,12]
- Optic neuropathy and sensorineural hearing loss are reported with chronic toluene exposure.[10-11]
Course
Inhalant intoxication can mimic a wide range of toxic, metabolic, and primary psychiatric conditions, and inhalant-related neurotoxicity overlaps with demyelinating and nutritional disorders. The differential narrows quickly with collateral history and targeted examination.
Substance-related differentials
- Alcohol intoxication: longer time course (hours), distinctive odor, positive breath or blood alcohol level.[6]
- Sedative-hypnotic intoxication (, ): similar GABAergic picture, but onset is slower and duration substantially longer.[6]
- Cannabis or hallucinogen intoxication: prominent perceptual changes without the rapid CNS depression and ataxia typical of inhalants.[6]
- Opioid intoxication: miosis and respiratory depression dominate; pinpoint pupils are uncommon in inhalant intoxication.[6]
Medical and neurologic mimics
- Toxic leukoencephalopathy from other causes (chemotherapy, carbon monoxide, heroin pyrolysate inhalation "chasing the dragon"): MRI pattern and exposure history differentiate.[10-11]
- Multiple sclerosis: relapsing-remitting course, oligoclonal bands on CSF, and characteristic lesion distribution differ from the diffuse symmetric pattern of toluene leukoencephalopathy.[10]
- B12 deficiency from other causes (pernicious anemia, malabsorption): indistinguishable clinically and radiographically from nitrous oxide-induced deficiency; methylmalonic acid and homocysteine are elevated in both.[9]
- Cerebellar disease (alcohol-related degeneration, paraneoplastic, hereditary ataxia): chronicity and exposure history are differentiating.[11]
- Hypoxia or hypoglycemia: acutely indistinguishable from inhalant intoxication; check glucose and oxygenation in any altered adolescent.[6]
Psychiatric mimics
- Primary psychotic disorder: inhalant intoxication can produce transient hallucinations; persistence beyond 24-48 hours of abstinence argues against an inhalant cause.[13]
- Conduct disorder: frequently comorbid rather than alternative; substance-related diagnoses are made independently.[1,13]
| Feature | Inhalant intoxication | Alcohol intoxication | Benzodiazepine intoxication |
|---|---|---|---|
| Onset | Seconds | 15-30 min | 15-60 min |
| Duration | 15-45 min | Hours | Hours |
| Odor | Solvent on breath/clothing | Ethanol on breath | None |
| Pupils | Normal or mydriatic | Normal | Normal |
| Skin findings | Perioral/perinasal rash | None | None |
| First-line acute care | Supportive; ECG monitoring | Supportive; thiamine | Supportive; flumazenil rarely |
Inhalant use is frequently missed because routine toxicology screens do not detect it and patients rarely volunteer the history. A high index of suspicion, focused examination, and selective laboratory and imaging studies establish the diagnosis and identify neurotoxic complications.
History
- Ask directly and non-judgmentally about huffing, sniffing, bagging, dusting, whippets, and poppers; brand names of common products (correction fluid, spray paint, glue, computer duster) are recognized more readily than "inhalants".[6,15]
- Document agent, route (huffing from a soaked rag, bagging from a plastic bag, direct nozzle inhalation), frequency, duration, and most recent use.[6,15]
- Screen for polysubstance use, suicidality, and conduct symptoms in every case.[1,3]
Physical examination
- Inspect perioral, perinasal, and hand skin for rash, staining, or chemical burns.[6]
- Smell breath, hair, and clothing for solvent odor.[6]
- Neurological examination: cerebellar testing (finger-to-nose, gait, tandem gait), cranial nerves (visual acuity, hearing), and distal sensorimotor examination for neuropathy.[10-12]
Rating scales and structured tools
- No inhalant-specific validated rating scale is in wide clinical use; general substance-use screens (CRAFFT for adolescents, ASSIST) include inhalant items.[15]
- The and are insensitive to early toluene leukoencephalopathy; formal neuropsychological testing detects executive and processing-speed deficits earlier.[10-11]
Laboratory and imaging
- Routine urine drug screens do NOT detect volatile hydrocarbons; specialty laboratories can measure hippuric acid (toluene metabolite), 2,5-hexanedione (n-hexane metabolite), or trichloroacetic acid, but turnaround is slow and clinical utility is limited.[6,15]
- Obtain ECG during acute intoxication to evaluate for arrhythmia, particularly with fuel-gas or aerosol exposure.[6,8]
- Baseline labs: complete blood count, comprehensive metabolic panel including liver enzymes and creatinine, creatine kinase if exertional or prolonged use, and pregnancy test in reproductive-age patients.[6,15]
- Methylmalonic acid, homocysteine, and serum B12 in chronic nitrous oxide users or anyone with myelopathy or neuropathy.[9]
- MRI brain (T2/FLAIR) when chronic toluene use is suspected or unexplained neurological signs are present.[10-11]
- Nerve conduction studies for suspected peripheral neuropathy.[12]
A negative urine drug screen does not rule out inhalant use; standard immunoassays do not detect volatile hydrocarbons, nitrous oxide, or nitrites.[6,15]
No medication has regulatory approval for inhalant use disorder, and the evidence base for pharmacotherapy is limited to small case series. Management centers on acute stabilization, treatment of neurotoxic complications, psychosocial intervention, and addressing comorbid psychiatric and substance use disorders.[6,15-16]
Acute intoxication management
- Remove the patient from the inhalant source and provide a calm, low-stimulation environment to reduce catecholamine surge and arrhythmia risk.[6,8]
- Supportive care: airway, breathing, circulation; supplemental oxygen if hypoxic.[6]
- Cardiac monitoring with continuous ECG during the intoxication period; beta-blockade is the preferred agent for catecholamine-sensitized arrhythmia rather than epinephrine, which can precipitate ventricular fibrillation.[6,8]
- Avoid sympathomimetics where possible; treat agitation with low-dose benzodiazepines if pharmacologic restraint is necessary.[6]
Do not administer epinephrine for cardiac arrest in suspected inhalant-related arrhythmia unless no alternative exists; the sensitized myocardium can develop refractory ventricular fibrillation.[6,8]
Pharmacotherapy
- No medication is approved by the FDA or recommended in major guidelines as a primary treatment for inhalant use disorder.[15-16]
- Limited evidence suggests buspirone, lamotrigine, and carbamazepine may reduce craving or use in small open-label series; high-quality evidence is lacking.[16]
- Treat comorbid disorders (, depressive disorders, ) per their own evidence base; effective treatment of comorbidity is associated with improved substance-use outcomes.[1,15]
- For nitrous oxide-induced B12 deficiency, parenteral cyanocobalamin 1000 mcg IM daily then weekly with neurological recovery monitoring is standard, though randomized data are absent.[9]
Psychotherapy
- Limited evidence suggests and adapted from other substance use disorders are reasonable first-line psychosocial approaches.[15-16]
- Family-based interventions (multidimensional family therapy, family behavior therapy) have the strongest evidence base in adolescent substance use disorders broadly and are commonly recommended for adolescent inhalant users.[15,17]
- has a robust evidence base in stimulant and cannabis use disorders; its application to inhalant use disorder is limited and exploratory.[16]
Neuromodulation
- No neuromodulation intervention has established a role in inhalant use disorder.[16]
Adjunctive
- Address housing instability, school engagement, and child protective concerns; in many jurisdictions, inhalant use in a minor triggers mandated reporting obligations.[15]
- Community-level interventions targeting product availability (e.g., paint-stripper formulations, butane fuel sales) have reduced incidence in some Indigenous communities, most notably the introduction of low-aromatic fuel (Opal) in remote Australian communities.[5]
Effective management of inhalant use disorder is frequently delivered by adolescent medicine and pediatric addiction services rather than adult addiction programs; refer accordingly.[15]
| Intervention | Evidence base/Comparator | Benefits | Harms | Certainty | Notes |
|---|---|---|---|---|---|
| Supportive care for acute intoxication | Expert opinion; case series[6,8] | Reduces arrhythmia and injury risk | None inherent | expert_opinion | Avoid sympathomimetics |
| Beta-blockade for catecholamine-sensitized arrhythmia | Case reports; toxicology consensus[6,8] | Restores rhythm; avoids epinephrine harm | Bradycardia, hypotension | low | Toxicology guidance, not RCT |
| Motivational interviewing / CBT | Extrapolated from other SUDs; small inhalant studies[15-16] | Modest reduction in use | Minimal | low | First-line psychosocial approach |
| Family-based therapy (adolescents) | RCTs in adolescent SUDs; limited inhalant-specific data[15,17] | Improves engagement and outcomes | Minimal | moderate | Strongest psychosocial evidence in adolescents |
| Pharmacotherapy (buspirone, lamotrigine, carbamazepine) | Open-label series[16] | Possible craving reduction | Drug-specific adverse effects | very_low | No FDA approval; not guideline-recommended |
| Parenteral B12 for nitrous oxide myelopathy | Case series[9] | Neurological recovery | Injection-site reactions | low | Standard of care despite no RCT |
| Community-level supply reduction (low-aromatic fuel) | Population-level program evaluations[5] | Reduced incidence in target communities | None inherent | moderate | Indigenous community context |
Inhalants carry the highest per-exposure mortality and neurotoxicity risk of commonly used recreational substances, and the evidence base for treatment is small and methodologically limited.
Acute harms
- Sudden sniffing death from ventricular arrhythmia, a leading cause of inhalant-related fatality.[6,8]
- Asphyxiation from plastic-bag use (bagging) and aspiration of vomitus during intoxication.[6]
- Burns and explosions from flammable hydrocarbons.[6]
- Traumatic injury and motor vehicle crash from impaired coordination.[6]
Chronic harms
- Irreversible toluene leukoencephalopathy with persistent cognitive, cerebellar, and pyramidal deficits.[10-11]
- Peripheral neuropathy from n-hexane and nitrous oxide; partial recovery is possible with cessation and B12 repletion for nitrous oxide cases.[9,12]
- Renal tubular acidosis (toluene), hepatotoxicity (chlorinated hydrocarbons), and bone marrow suppression (benzene-containing products).[6]
- Optic neuropathy and sensorineural hearing loss with chronic toluene exposure.[10-11]
- Methemoglobinemia from nitrite use, presenting with cyanosis unresponsive to oxygen.[4]
Evidence limitations
- Small sample sizes, short follow-up, and high attrition characterize the inhalant treatment literature.[16]
- Polysubstance use complicates attribution of cognitive and psychiatric findings to inhalants specifically.[1,3]
- Most evidence on neurotoxicity derives from case series and small cross-sectional studies rather than prospective cohorts.[10-11]
- Adolescent-focused trials are underrepresented relative to the population most affected.[15-16]
Inhalant-related disorders disproportionately affect adolescents and several specific populations, and management is tailored accordingly.
Pediatric and adolescent
- Adolescents constitute the majority of inhalant users; assessment should include developmental, school, and family functioning.[1,15]
- Mandated reporting and child protective involvement may apply when inhalant use occurs in a minor; clinicians should know jurisdiction-specific obligations.[15]
- Family-based and school-based interventions have the strongest evidence base in adolescents.[15,17]
Geriatric
- Inhalant use disorder is rare in older adults; new-onset use in this group should prompt evaluation for cognitive impairment, -related disinhibition, or undisclosed long-standing use.[15]
Perinatal
- Inhalant use during pregnancy is associated with fetal solvent syndrome, with craniofacial features resembling fetal alcohol syndrome, growth restriction, and neurodevelopmental impairment.[18]
- Prenatal toluene exposure has been associated with renal tubular acidosis in the newborn.[18]
- Screen all pregnant patients for inhalant use; and engagement with substance-use treatment are first-line.[15,18]
Comorbid medical illness
- Conditions predisposing to arrhythmia (long QT syndrome, prior structural heart disease) may amplify the risk of sudden sniffing death.[6,8]
- Pre-existing renal, hepatic, or hematologic disease amplifies organ-specific toxicity.[6]
Comorbid substance use
- Polysubstance use is the norm; evaluate and treat all substances concurrently.[1,3]
Cultural considerations
- Indigenous and remote-community youth in Australia, Canada, the US, and elsewhere carry elevated prevalence; community-engaged interventions, including supply-side measures, have demonstrated population-level benefit.[5]
- Stigma surrounding inhalant use is high; non-judgmental, harm-reduction-informed approaches improve engagement.[15]
Most adolescent inhalant users experiment briefly and discontinue without lasting harm; a smaller subset develops persistent use with significant neurotoxic, psychiatric, and social sequelae.
Natural history
- The majority of adolescent users do not progress to inhalant use disorder, and inhalant use typically declines through late adolescence as users transition to other substances or stop entirely.[1,3]
- Persistent use into adulthood is uncommon but is associated with cumulative neurotoxicity and high psychiatric and social burden.[10-11]
Outcomes
- Cognitive deficits from toluene leukoencephalopathy are largely irreversible; cessation arrests progression but rarely restores pre-morbid function.[10-11]
- Peripheral neuropathy from nitrous oxide use can improve substantially with cessation and B12 repletion; n-hexane neuropathy recovers more slowly and incompletely.[9,12]
- Lifetime suicide attempt rates are elevated among individuals with inhalant use disorder relative to other substance use disorders.[3]
- Mortality is elevated through sudden sniffing death, suicide, and unintentional injury.[3,6,8]
Acute inhalant intoxication is a medical emergency when cardiac, respiratory, or neurological compromise is present, and the safety evaluation extends to suicide and child protective concerns.
Hospitalization criteria
- Arrhythmia, hemodynamic instability, hypoxia, or persistent altered mental status warrants emergency department evaluation and admission as indicated.[6,8]
- Severe agitation, suicidal ideation with intent or plan, or psychosis persisting beyond intoxication may require psychiatric hospitalization.[15]
- New neurological signs (focal deficits, encephalopathy, myelopathy) warrant inpatient evaluation for neurotoxicity.[10-11]
Suicide risk
- Lifetime suicide attempt prevalence is elevated in inhalant use disorder; assess suicidality at every contact.[3]
- Comorbid depressive disorder, conduct disorder, and substance use disorders compound risk.[1,3]
Agitation management
- Low-stimulation environment, verbal de-escalation, and low-dose benzodiazepines if pharmacologic management is required.[6]
- Avoid sympathomimetics; physical restraint should be a last resort given arrhythmia risk during exertion.[6,8]
Safety-relevant comorbidities
Several aspects of inhalant-related disorders remain contested or poorly characterized, reflecting the limited research investment relative to disease burden.
- Existence of a clinically meaningful inhalant withdrawal syndrome is contested: DSM-5-TR does not recognize withdrawal as a distinct entity, while ICD-11 includes it; clinical reports describe irritability, sleep disturbance, and craving in heavy users, but controlled data are sparse.[13-14]
- Classification of nitrous oxide and nitrites alongside hydrocarbon inhalants is pharmacologically inconsistent; DSM-5-TR codes them separately under "other (or unknown) substance", and some experts argue for distinct diagnostic categories.[13]
- Reversibility of toluene leukoencephalopathy with prolonged abstinence is debated; some imaging studies report partial regression of white matter changes, while neuropsychological deficits typically persist.[10-11]
- The role of pharmacotherapy (buspirone, lamotrigine, carbamazepine, baclofen) remains unsettled; existing data are limited to small open-label series and have not been replicated in adequately powered trials.[16]
- Rising recreational use of nitrous oxide ("galaxy gas", whippets, large "cream charger" canisters) has produced a recent surge in subacute combined degeneration cases in young adults, with public health and regulatory responses still developing.[9]
- Whether contingency management, well-established in stimulant use disorders, achieves comparable effect sizes in inhalant use disorder is not yet established.[16]
- Inhalant use peaks in early adolescence and is one of the few substance classes for which 8th-grade past-year use exceeds 12th-grade use.[1-2]
- DSM-5-TR inhalant use disorder applies only to hydrocarbon-based inhalants; nitrous oxide and nitrites are coded as "other (or unknown) substance use disorder".[13]
- DSM-5-TR does not recognize inhalant withdrawal as a diagnosis, while ICD-11 does.[13-14]
- Sudden sniffing death results from catecholamine-induced ventricular arrhythmia in a myocardium sensitized by halogenated hydrocarbons or fuel gases.[6,8]
- Beta-blockade is preferred over epinephrine for inhalant-related cardiac arrhythmia.[6,8]
- Toluene produces a characteristic diffuse leukoencephalopathy with cerebellar, brainstem, and corticospinal tract involvement on MRI.[10-11]
- n-Hexane causes peripheral neuropathy via its metabolite 2,5-hexanedione.[12]
- Nitrous oxide inactivates vitamin B12 by oxidizing cobalt, producing subacute combined degeneration with elevated methylmalonic acid and homocysteine.[9]
- Routine urine drug screens do not detect volatile hydrocarbons, nitrous oxide, or nitrites.[6,15]
- "Glue sniffer's rash" describes perioral and perinasal dermatitis from repeated solvent exposure.[6]
- Prenatal solvent exposure produces fetal solvent syndrome with craniofacial features resembling fetal alcohol syndrome and neurodevelopmental impairment.[18]
- Introduction of low-aromatic Opal fuel reduced petrol-sniffing prevalence in remote Australian Indigenous communities.[5]
- No pharmacotherapy is FDA-approved for inhalant use disorder; management is supportive and psychosocial.[15-16]
- Family-based therapy has the strongest psychosocial evidence base in adolescent substance use disorders, including inhalant use.[15,17]
- Methemoglobinemia presenting with oxygen-unresponsive cyanosis suggests nitrite use.[4]
No external funding. No conflicts of interest declared. Peer-review status: pending.
- 1.Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the National Survey on Drug Use and Health. Rockville, MD: SAMHSA; 2023.
- 2.Johnston LD, Miech RA, O'Malley PM, Bachman JG, Schulenberg JE, Patrick ME. Monitoring the Future National Survey Results on Drug Use, 1975-2023: Overview and Detailed Results for Secondary School Students. Ann Arbor, MI: Institute for Social Research, University of Michigan; 2024.
- 3.Howard MO, Bowen SE, Garland EL, Perron BE, Vaughn MG. Inhalant use and inhalant use disorders in the United States. Addict Sci Clin Pract. 2011;6(1):18-31. PMID: 22003419.PMID: 22003419
- 4.Romanelli F, Smith KM, Thornton AC, Pomeroy C. Poppers: epidemiology and clinical management of inhaled nitrite abuse. Pharmacotherapy. 2004;24(1):69-78. doi:10.1592/phco.24.1.69.34801.doi:10.1592/phco.24.1.69.34801.
- 5.d'Abbs P, Shaw G. Evaluation of the impact of Opal fuel: final report. Canberra: Department of Health and Ageing; 2008.
- 6.Williams JF, Storck M; American Academy of Pediatrics Committee on Substance Abuse, Committee on Native American Child Health. Inhalant abuse. Pediatrics. 2007;119(5):1009-1017. doi:10.1542/peds.2007-0470.doi:10.1542/peds.2007-0470.
- 7.Balster RL, Cruz SL, Howard MO, Dell CA, Cottler LB. Classification of abused inhalants. Addiction. 2009;104(6):878-882. doi:10.1111/j.1360-0443.2008.02494.x.doi:10.1111/j.1360-0443.2008.02494.x.
- 8.Bowen SE. Two serious and challenging medical complications associated with volatile substance misuse: sudden sniffing death and fetal solvent syndrome. Subst Use Misuse. 2011;46(Suppl 1):68-72. doi:10.3109/10826084.2011.580220.doi:10.3109/10826084.2011.580220.
- 9.Systematic reviewGarakani A, Jaffe RJ, Savla D, et al. Neurologic, psychiatric, and other medical manifestations of nitrous oxide abuse: a systematic review of the case literature. Am J Addict. 2016;25(5):358-369. doi:10.1111/ajad.12372.doi:10.1111/ajad.12372.
- 10.Filley CM, Halliday W, Kleinschmidt-DeMasters BK. The effects of toluene on the central nervous system. J Neuropathol Exp Neurol. 2004;63(1):1-12. doi:10.1093/jnen/63.1.1.doi:10.1093/jnen/63.1.1.
- 11.Systematic reviewYucel M, Takagi M, Walterfang M, Lubman DI. Toluene misuse and long-term harms: a systematic review of the neuropsychological and neuroimaging literature. Neurosci Biobehav Rev. 2008;32(5):910-926. doi:10.1016/j.neubiorev.2008.01.006.doi:10.1016/j.neubiorev.2008.01.006.
- 12.Spencer PS, Schaumburg HH. Organic solvent neurotoxicity. Facts and research needs. Scand J Work Environ Health. 1985;11(Suppl 1):53-60.
- 13.TextbookAmerican Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed, text rev. Washington, DC: American Psychiatric Association Publishing; 2022.
- 14.TextbookWorld Health Organization. International Classification of Diseases, Eleventh Revision (ICD-11). Geneva: WHO; 2019.
- 15.GuidelineAmerican Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with substance use disorders. J Am Acad Child Adolesc Psychiatry. 2005;44(6):609-621.
- 16.Systematic reviewKonghom S, Verachai V, Srisurapanont M, et al. Treatment for inhalant dependence and abuse. Cochrane Database Syst Rev. 2010;(12):CD007537. doi:10.1002/14651858.CD007537.pub2.doi:10.1002/14651858.CD007537.pub2.
- 17.Hogue A, Henderson CE, Ozechowski TJ, Robbins MS. Evidence base on outpatient behavioral treatments for adolescent substance use: updates and recommendations 2007-2013. J Clin Child Adolesc Psychol. 2014;43(5):695-720. doi:10.1080/15374416.2014.915550.doi:10.1080/15374416.2014.915550.
- 18.Jones HE, Balster RL. Inhalant abuse in pregnancy. Obstet Gynecol Clin North Am. 1998;25(1):153-167. doi:10.1016/s0889-8545(05)70363-6.doi:10.1016/s0889-8545(05)70363-6.
More on these topics
Tobacco-Related Disorders: Diagnosis, Neurobiology, and Evidence-Based Treatment
Clinical reference on tobacco use disorder and nicotine withdrawal — diagnosis, neurobiology, and first-line pharmacologic and behavioral treatment.
Tobacco-Related DisordersSubstance-Related and Addictive DisordersStimulant-Related Disorders: Clinical Overview and Management
Evidence-based overview of stimulant use, intoxication, withdrawal, and stimulant use disorder for clinicians and trainees.
Stimulant-Related DisordersPsychosisStimulant UseSedative, Hypnotic, or Anxiolytic-Related Disorders
Clinical overview of sedative-hypnotic use disorder, intoxication, and withdrawal, with management of life-threatening benzodiazepine and barbiturate withdrawal.
Sedative, Hypnotic, or Anxiolytic-Related DisordersSubstance-Related and Addictive DisordersOpioid-Related Disorders: Diagnosis, Pharmacotherapy, and Overdose Management
Clinical reference on opioid use disorder and opioid overdose covering DSM-5-TR diagnosis, MOUD with methadone, buprenorphine, and naltrexone, and naloxone reversal.
Opioid-Related DisordersSubstance-Related and Addictive DisordersGambling Disorder: Diagnosis, Neurobiology, and Evidence-Based Management
Clinical reference on gambling disorder covering DSM-5-TR criteria, reward-circuit neurobiology, screening, and pharmacologic and psychotherapeutic management.
Gambling DisorderSubstance-Related and Addictive DisordersHallucinogen-Related Disorders: Diagnosis, Pharmacology, and Clinical Management
Clinical reference on hallucinogen intoxication, persisting perception disorder, and use disorder, with DSM-5-TR criteria and evidence-based management.
Hallucinogen-Related DisordersSubstance-Related and Addictive DisordersCannabis-Related Disorders: Intoxication, Withdrawal, Use Disorder, and Cannabis-Induced Psychosis
A clinical reference on cannabis use disorder, intoxication, withdrawal, and induced syndromes, including diagnosis, treatment, and high-yield exam points.
Cannabis-Related DisordersSubstance-Related and Addictive DisordersCaffeine-Related Disorders: Intoxication, Withdrawal, and Use Disorder
A clinical guide to DSM-5-TR caffeine intoxication and withdrawal, the proposed caffeine use disorder, and evidence-based management.
Caffeine-Related DisordersSubstance-Related and Addictive Disorders